Merck announces favorable English Court ruling on name use
Court says MSD breached an agreement with Merck by using "Merck" alone either as a trade mark or a name in the UK.
Merck has secured a favorable ruling in the English High Court following almost 3 years of litigation with US-based Merck Sharp & Dohme Corp. (MSD) regarding the use of the term "Merck".
In its judgement the English High Court stated that MSD had breached an agreement with the company by using "Merck" alone in the UK either as a trade mark or a name, online or offline. Merck and MSD had entered the agreement in 1955 and amended it in 1970. According to this agreement, Merck is entitled to use the name everywhere in the world, except the US and Canada.
"Our objective has been to protect the status quo established in the existing agreement,” said Friederike Rotsch, General Counsel at Merck. “Therefore, we are pleased that the English court has upheld our argument that MSD’s use of our name and brand 'MERCK' in our territories is beyond the limits agreed with MSD."
Merck relaunched its brand identity last year to reflect the transformation into a global science and technology company with three strong businesses in Healthcare Life Science and Performance Material and create a distinct identity vis-à-vis its patients, customers and investors across various industries and geographies.
The judge said Merck was entitled to an order to prevent MSD from describing itself in any printed or digital material addressed to the UK as "'Merck" alone, and restraining MSD's use of the trade mark "MERCK" alone. The judge also held that MSD’s use of “Merck” as part of branding on its global websites were directed to the UK and infringed Merck’s trade mark rights in the UK.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance